Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (Nasdaq: LFMD) is a virtual primary care and pharmacy company whose news flow centers on telehealth expansion, clinical program development, strategic collaborations, and capital markets activity. As a provider of virtual healthcare services across more than 200 conditions, LifeMD regularly issues updates on its weight management, women’s health, men’s health, behavioral health, and primary care offerings, as well as on its pharmacy and compounding pharmacy capabilities.
News about LifeMD often highlights clinical and commercial partnerships, particularly in obesity and metabolic health. The company has announced an expanded collaboration with Novo Nordisk, under which LifeMD is recognized as a telehealth partner offering FDA-approved GLP‑1 therapies such as Wegovy and Ozempic. Press releases describe new product availability, including the Wegovy oral pill, and cash-pay pricing initiatives designed to broaden access to branded GLP‑1 medications through LifeMD’s virtual weight management programs.
Investors and observers can also expect financial and corporate updates in LifeMD’s news stream. These include quarterly earnings releases, segment performance commentary, and disclosures about strategic transactions such as the divestiture of its majority interest in WorkSimpli Software LLC. The company’s transition into a pure-play virtual care and pharmacy platform, along with its efforts to strengthen its balance sheet, are recurring themes in management commentary.
Additional news items cover capital structure and governance developments, such as the authorization of dividends on the company’s 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) and the establishment of a senior secured revolving credit facility with Citizens Bank, N.A. Regulatory and reporting updates, including Forms 8‑K and notifications of late filings related to financial statement adjustments, also appear in the company’s announcements.
For those following LFMD, this news page provides a centralized view of LifeMD’s earnings reports, clinical program launches, partnership expansions, financing arrangements, and regulatory disclosures, offering context on how the company is evolving its virtual care and pharmacy platform over time.
LifeMD (NASDAQ:LFMD) has expanded its collaboration with Novo Nordisk to offer Ozempic® at $499 per month to eligible self-pay patients through its virtual care platform. The offering targets uninsured patients and those whose insurance doesn't cover GLP-1 therapies.
Through integration with NovoCare® Pharmacy, patients can access all FDA-approved dose strengths of Ozempic® and Wegovy® within LifeMD's comprehensive care platform, which includes virtual consultations, clinical support, diagnostic testing, and pharmacy coordination. The platform also provides access to Lilly's Zepbound® through integration with LillyDirect pharmacy provider.
Ozempic® is FDA-approved for type 2 diabetes, which affects approximately 36 million Americans. This collaboration aims to improve accessibility to authentic, FDA-approved GLP-1 treatments at competitive self-pay prices.
LifeMD (NASDAQ:LFMD), a virtual primary care services provider, announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 9, 2025 at the Metropolitan Club in New York City. The company's management team will conduct one-on-one meetings with investors during the conference.
LifeMD (NASDAQ:LFMD), a virtual primary care services provider, has declared its quarterly dividend for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP). The company will distribute a cash dividend of $0.5546875 per share to preferred stockholders of record as of October 3, 2025, with the payment scheduled for October 15, 2025.
LifeMD (Nasdaq: LFMD) has expanded its affiliated pharmacy services to include non-sterile compounding capabilities for oral and topical medications. This enhancement follows the August 2024 launch of their commercial pharmacy, which can process up to 5,000 prescriptions daily.
The expanded facility will enable LifeMD to formulate customized medications, including allergen-free and combination products not commercially available. Operating under FDA's 503A designation, the pharmacy is currently licensed in 13 states and aims to secure licenses across all 50 states within 12 months.
This strategic expansion supports LifeMD's core service areas in men's and women's health and dermatology while reducing third-party provider dependence and improving operational efficiency.
LifeMD (NASDAQ:LFMD), a virtual primary care services provider, has announced its participation in three major investor conferences in September 2025:
The company will attend the Cantor Fitzgerald Global Healthcare Conference (Sept 3-5) featuring a fireside chat, the H.C. Wainwright Global Investment Conference (Sept 8-10) with an on-demand presentation, and the Lake Street Capital Markets Best Ideas Growth Conference (Sept 11). Management will be available for one-on-one meetings with investors at all three events.
LifeMD (NASDAQ:LFMD), a virtual primary care services provider, reported strong Q2 2025 financial results with total revenue increasing 23% year-over-year to $62.2 million. The company's telehealth segment showed impressive growth, with revenue up 30% to $48.6 million and adjusted EBITDA surging 560% to $3.4 million.
Key operational highlights include reaching 297,000 active telehealth subscribers, launching a nationwide behavioral health offering, and acquiring a virtual women's health brand. The company generated over $8 million in operating cash flow and exited the quarter with $36.2 million in cash, having fully repaid all senior debt.
However, LifeMD revised its full-year 2025 guidance downward due to temporary challenges in its Rex MD business, now expecting total revenue of $250-255 million and adjusted EBITDA of $27-29 million, compared to previous guidance of $268-275 million and $31-33 million respectively.
Medifast (NYSE: MED) reported challenging second quarter 2025 results, with revenue declining 37.4% to $105.6 million from $168.6 million in Q2 2024. The company's active OPTAVIA coaches decreased 32.7% to 22,800, while revenue per coach fell to $4,630. Despite operational challenges, Medifast maintained a strong balance sheet with $162.7 million in cash and no debt.
Net income was $2.5 million ($0.22 per share), including a $2.0 million gain from LifeMD investment. The company faces headwinds from GLP-1 weight loss medications but highlighted positive clinical findings showing their OPTAVIA 5 & 1 Plan preserves 98% of lean mass. For Q3 2025, Medifast projects revenue between $70-90 million with EPS ranging from ($0.60) to $0.00.
LifeMD (NASDAQ:LFMD), a virtual primary care services provider, announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The event will take place at the InterContinental Boston from August 12-14, 2025.
Company management will engage in a fireside chat on August 13th at 8:30 AM ET and conduct one-on-one investor meetings during August 12-13. Interested investors can register through their Canaccord Genuity representative.
LifeMD (NASDAQ: LFMD), a virtual healthcare services provider, has announced key leadership appointments. Shayna Webb Dray, previously Senior VP of Operations, has been promoted to Chief Operating Officer. Webb Dray, who joined LifeMD in 2021, brings over 15 years of operations and supply chain experience.
The company also expanded Jessica Friedeman's role to Chief Marketing and Product Officer and promoted Jacob Ellison to Chief Analytics Officer, where he will lead data strategy and AI innovation. These appointments aim to strengthen LifeMD's operational excellence and support its expansion into new healthcare verticals.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern time.
LifeMD operates through a vertically integrated platform featuring a 50-state affiliated medical group, a 22,500-square-foot pharmacy, and a U.S.-based patient care center. The company provides telemedicine services, laboratory and pharmacy access, and specialized treatment for over 200 medical conditions, including primary care, men's and women's health, weight management, and hormone therapy.